These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 30817996)

  • 1. Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis.
    Salgado CL; Dias EL; Stringari LL; Covre LP; Dietze R; Lima Pereira FE; de Matos Guedes HL; Rossi-Bergmann B; Gomes DCO
    Microbes Infect; 2019; 21(7):328-335. PubMed ID: 30817996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with Leishmania (infantum) chagasi.
    Leal JM; Mosquini M; Covre LP; Stagmiller NP; Rodrigues RR; Christensen D; de Matos Guedes HL; Rossi-Bergmann B; Gomes DC
    Parasitology; 2015 Nov; 142(13):1640-6. PubMed ID: 26394776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis.
    Helou DG; Mauras A; Fasquelle F; Lanza JS; Loiseau PM; Betbeder D; Cojean S
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009627. PubMed ID: 34403413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal but not subcutaneous vaccination with LaAg allows rapid expansion of protective immunity against cutaneous leishmaniasis.
    Pereira Silva Bezerra I; Amaral Abib M; Rossi-Bergmann B
    Vaccine; 2018 Apr; 36(18):2480-2486. PubMed ID: 29599090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P; Paik D; Naskar K; Chakraborti T
    Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal immunization with LACK-DNA promotes protective immunity in hamsters challenged with Leishmania chagasi.
    DE Oliveira Gomes DC; DA Silva Costa Souza BL; DE Matos Guedes HL; Lopes UG; Rossi-Bergmann B
    Parasitology; 2011 Dec; 138(14):1892-7. PubMed ID: 21867591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice.
    Pratti JE; Ramos TD; Pereira JC; da Fonseca-Martins AM; Maciel-Oliveira D; Oliveira-Silva G; de Mello MF; Chaves SP; Gomes DC; Diaz BL; Rossi-Bergmann B; de Matos Guedes HL
    Parasit Vectors; 2016 Oct; 9(1):534. PubMed ID: 27716449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal delivery of LaAg vaccine improves immunity of aged mice against visceral Leishmaniasis.
    Salgado CL; Corea AFM; Covre LP; Fonseca-Martins AMD; Falqueto A; Guedes HLM; Rossi-Bergmann B; Gomes DCO
    Acta Trop; 2024 Apr; 252():107125. PubMed ID: 38280636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune induction by adjuvanted Leishmania donovani vaccines against the visceral leishmaniasis in BALB/c mice.
    Goyal DK; Keshav P; Kaur S
    Immunobiology; 2021 Mar; 226(2):152057. PubMed ID: 33545508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
    Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
    Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
    Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
    Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.
    de Jesus Pereira NC; Régis WC; Costa LE; de Oliveira JS; da Silva AG; Martins VT; Duarte MC; de Souza JR; Lage PS; Schneider MS; Melo MN; Soto M; Soares SA; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    Exp Parasitol; 2015 Jun; 153():180-90. PubMed ID: 25845753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
    Kaur J; Kaur T; Kaur S
    Acta Trop; 2011 Jul; 119(1):50-6. PubMed ID: 21530477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoencapsulated retinoic acid as a safe tolerogenic adjuvant for intranasal vaccination against cutaneous leishmaniasis.
    Bezerra IPS; Costa-Souza BLS; Carneiro G; Ferreira LAM; de Matos Guedes HL; Rossi-Bergmann B
    Vaccine; 2019 Jun; 37(28):3660-3667. PubMed ID: 31133469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.